Lynn Rose, PhD, to Retire from Benaroya Research Institute at Virginia Mason
Lynn M. Rose, PhD, chief of scientific administration at Benaroya Research Institute at Virginia Mason (BRI) has announced her retirement effective August 6. In her time at BRI, Dr. Rose made significant contributions in clinical research administration, business development and research compliance. First hired in 2012 as Director of Scientific Administration, she helped build new resources within the institute, including the Experimental Medical Unit and the BRITE Tumor Registry that expanded BRI’s cancer research program. She also had oversight responsibility for research compliance including the development of a centralized process for review and approval of institute policies and procedures. Much of her work involved successful collaborations with Virginia Mason Medical Center departments and staff.
“In her eight years with BRI, Dr. Rose has expanded support and resources for BRI’s talented researchers, facilitating important discoveries against diseases of the immune system, including the COVID-19 virus. BRI greatly benefitted from her extensive experience in biomedical research, leading to strong alliances with corporate, government and academic partners,” said Margaret McCormick, PhD, executive director and chief operating officer of BRI.
Rose has more than 30 years of experience in biomedical research, including positions in both academia and industry. Her industry experience has included direct responsibility for preclinical, clinical and regulatory programs. Dr. Rose previously served as Research Associate Professor, Department of Pediatrics, UW School of Medicine and as a faculty member of the Institute of Translational Health Sciences (ITHS). She also served as Director, Office of Regulatory and Clinical Affairs at Seattle Children’s Research Institute, Center for Clinical and Translational Research. She has a strong research background in immunology and autoimmune diseases and began her career as a basic research scientist.
In retirement, Lynn will remain in Seattle and expand her role at the University of Washington School of Pharmacy, where she teaches Biomedical Regulatory Affairs.